Skip to content
Clinical Trials – home

Rare diseases

Investigational molecules

Locations

Our offerNewsroom

NorwayBack to Norway

Clinical trials in Oslo – page 19

527 clinical trials in Oslo, Norway across 9 research sites. Every trial is listed in the EU Clinical Trials Register and updated daily.

NorwayOur site in NorwayKliniske-Studier.no(opens in a new tab)
Oslo at a glance
527
clinical trials
  • Research sites9
Type of trial
Recruitment status
Quick filters

527 trials in Oslo

Open in trial search

Type IIa hyperlipidaemia

Recruiting

Study on Long-Term Safety of Inclisiran for Patients with Familial Hypercholesterolemia Who Completed Previous Adolescent Studies

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:0–17 years · 18–64 years
  • Substances:Inclisiran
  • Sponsor:Novartis Pharma AG

Colorectal cancer

Recruiting

Study on Using ctDNA to Guide Treatment in Patients with Metastatic Colorectal Cancer Using Oxaliplatin, Capecitabine, Calcium Folinate, Irinotecan, and Fluorouracil

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Calcium Folinate
  • Sponsor:Region Midtjylland

Acute myeloid leukaemia

Recruiting

Study on Venetoclax and Drug Combination for Adults with Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndrome with Excess Blasts-2

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Cytarabine
  • Sponsor:Universitaetsklinikum Ulm AöR

Renal transplant

Recruiting

Study on Reducing Tacrolimus in Kidney Transplant Patients with Low Immunological Risk Using Tacrolimus, Mycophenolic Acid, and Prednisone

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Iohexol
  • Sponsor:Centre Hospitalier Universitaire De Nantes

Acute myeloid leukaemia

Recruiting

Study on the Safety and Effectiveness of Quizartinib for Children with Newly Diagnosed FLT3-ITD Positive AML and Normal NPM1

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:0–17 years · 18–64 years
  • Substances:Quizartinib Dihydrochloride
  • Sponsor:Princess Maxima Center For Pediatric Oncology

Neonatal alloimmune thrombocytopenia

Recruiting

Study on Nipocalimab for Reducing Risk of Fetal and Neonatal Alloimmune Thrombocytopenia in At-risk Pregnancies

Investigational
Countries:NorwayNorway
  • Participants:18–64 years
  • Substances:Nipocalimab
  • Sponsor:Janssen Cilag International

Mitral valve prolapse

Recruiting

Study on the Effect and Safety of Flecainide and Metoprolol for Patients with Arrhythmic Mitral Valve Prolapse

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Flecainide
  • Sponsor:Oslo University Hospital HF

Stress cardiomyopathy

Recruiting

Study on the Effects of Adenosine, Dipyridamole, and Apixaban in Patients with Takotsubo Syndrome

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Adenosine
  • Sponsor:Vaestra Goetalandsregionen

Atrial fibrillation+2

Recruiting

Study on Apixaban for Preventing Stroke in Patients with Atrial Fibrillation and Stage 5 Chronic Kidney Disease

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Apixaban
  • Sponsor:Karolinska University Hospital

Acute lymphocytic leukaemia

Recruiting

Study on Methotrexate and Dexamethasone for Infants Under One Year with Acute Lymphoblastic Leukemia

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:0–17 years
  • Substances:Asparaginase
  • Sponsor:Princess Maxima Center For Pediatric Oncology

Metastatic malignant melanoma

Recruiting

Study Comparing Subcutaneous and Intravenous Nivolumab and Relatlimab for Patients with Untreated Metastatic or Unresectable Melanoma

InvestigationalNo placebo
Countries:NorwayNorway
  • Participants:0–17 years · 18–64 years · 65+ years
  • Substances:Nivolumab
  • Sponsor:Bristol-Myers Squibb Services Unlimited Company

HER2 positive breast cancer

Recruiting

Study Comparing Trastuzumab Deruxtecan with Standard Treatment for Patients with HER2-positive Breast Cancer

Registered drugNo placebo
Countries:NorwayNorway
  • Participants:18–64 years · 65+ years
  • Substances:Aprepitant
  • Sponsor:Karolinska University Hospital

Other cities in Norway

The busiest research cities in the country

All 54 cities in Norway

Clinical research in Oslo

What the registry says about research in the country

01 Respiratory Medicine

Clinical trials focusing on pulmonary conditions and respiratory health, including studies on idiopathic pulmonary fibrosis and respiratory syncytial virus prevention in children.

  • IPF Treatment Evaluation
  • RSV Prevention Studies
  • Chronic Wet Cough Research

Innovative therapies being tested to improve lung function and patient outcomes.

02 Cardiovascular Research

Studies examining heart conditions and vascular health, with particular focus on heart failure and cardiovascular disease prevention.

  • Heart Failure Imaging Studies
  • Cardiovascular Disease Prevention
  • Hypovolemia Management

Advanced imaging techniques and therapeutic interventions being evaluated for cardiac conditions.

03 Oncology Studies

Comprehensive research into various cancer treatments, including trials for gastric, esophageal, and rare cancers.

  • Advanced Solid Tumors
  • Targeted Cancer Therapies
  • Multiple Myeloma Treatment

Novel therapeutic approaches combining immunotherapy with conventional treatments.

Back to NorwayAll countries
Clinical Trials Concierge

Prefer not to search? Our Concierge searches the trials for you.

Tell us about your condition – we search every trial in Europe and connect you with the right site.